Product image of Mogilarta (Hydrochlorothiazide, Telmisartan) supplied by GNH India

Mogilarta

Active Ingredient:
Hydrochlorothiazide, Telmisartan
Origin:
EU

Mogilarta (Hydrochlorothiazide, Telmisartan)

Hydrochlorothiazide and Telmisartan, the active ingredients in Mogilarta, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for adult use. They treat hypertension by reducing blood pressure in patients who require combined diuretic and ARB therapy.

GNH India supplies Mogilarta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Its distribution network ensures timely delivery across Europe, Asia and the Americas.

Manufacturer / TM Owner

Teva Gyógyszergyár Zrt

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mogilarta combines an angiotensin II receptor blocker and a thiazide diuretic to manage high blood pressure.
  • Hypertension: provides effective blood pressure reduction in patients requiring dual therapy.
  • Essential hypertension: lowers systolic and diastolic pressure when monotherapy is insufficient.
  • Cardiovascular risk reduction: contributes to decreased risk of stroke and heart attack by controlling hypertension.

How It Works

  • Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of water and electrolytes. The combined actions reduce peripheral vascular resistance and plasma volume, resulting in a synergistic decrease in arterial blood pressure.

Side Effects

Mogilarta may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

  • Dizziness
  • Headache
  • Fatigue
  • Increased urination
  • Electrolyte imbalance (low potassium)
  • Mild gastrointestinal discomfort

Serious or Rare Side Effects

  • Severe dehydration
  • Acute kidney injury
  • Hyperkalemia
  • Allergic rash or angioedema
  • Liver function abnormalities
  • Blood disorders such as leukopenia

Precautions & Warnings

  • Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.
  • Monitor renal function: assess serum creatinine and electrolytes before and during therapy.
  • Assess electrolytes: watch for low potassium or sodium levels.
  • Avoid in severe hepatic impairment: use only if benefits outweigh risks.
  • Caution in patients with gout: diuretic component may raise uric acid.
  • Pregnancy and lactation: consult healthcare provider before use.
  • Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Avoid Interactions

Mogilarta may interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid)

  • Concomitant use with other ARBs or ACE inhibitors: risk of additive hypotension and renal dysfunction.
  • Potassium‑sparing diuretics or supplements: may cause hyperkalemia.
  • NSAIDs: can diminish antihypertensive effect and impair renal function.
  • Lithium: increased lithium levels and toxicity.
  • Cyclosporine: heightened risk of nephrotoxicity.

Moderate Interactions (Monitor Closely)

  • Antidiabetic drugs: may need dose adjustment due to improved glycemic control.
  • Beta‑blockers: additive blood pressure lowering.
  • Digoxin: monitor serum levels.
  • Corticosteroids: may reduce diuretic efficacy.
  • Alcohol: can enhance hypotensive effect.

Frequently Asked Questions

Mogilarta is prescribed to lower elevated blood pressure in adults with hypertension. It combines an angiotensin II receptor blocker and a thiazide diuretic, providing a dual mechanism that helps achieve target blood pressure when single‑agent therapy is insufficient.

Telmisartan blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide reduces sodium‑chloride reabsorption in the distal tubule, promoting diuresis. Together they lower vascular resistance and plasma volume, producing a synergistic antihypertensive effect.

The dose of Mogilarta is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule in accordance with local guidelines.

Safety of Mogilarta in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Mogilarta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mogilarta offers a fixed‑dose combination of an ARB and a thiazide diuretic, which can simplify regimens compared with taking two separate pills. This combination often provides better blood‑pressure control than monotherapy and may reduce pill burden, but choice of therapy should be individualized.

Mogilarta tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mogilarta is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe dehydration, acute kidney injury, hyperkalemia, allergic reactions such as angioedema, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like rapid weight loss, swelling, difficulty breathing, or severe rash.

Mogilarta is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, or those taking other ARBs or ACE inhibitors in combination. Caution is also advised for individuals with severe hepatic disease, electrolyte disturbances, or a history of angioedema.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hydrochlorothiazide, Telmisartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT